MANUFACTURING COMPLIANCE FOR MODULAR RNA DRUG PRODUCTION

1. INTRODUCTION

Modular RNA drug production is a manufacturing approach in which reusable production platforms, standardised processes, and interchangeable RNA sequences or formulation components are used to develop different therapeutic products. Applications include messenger RNA (mRNA) vaccines, personalised cancer vaccines, and other RNA-based medicines.

Although modular manufacturing can accelerate product development, it creates regulatory challenges involving product consistency, raw-material qualification, process validation, contamination control, stability, and changes to manufacturing methods. Reusing a platform does not automatically authorise the manufacture or sale of every new RNA product.

In India, compliance is governed principally by the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, the New Drugs and Clinical Trials Rules, 2019, applicable Good Manufacturing Practices (GMP), and relevant Central Drugs Standard Control Organisation (CDSCO) requirements. The precise obligations depend on the product category, intended use, manufacturing process, and applicable approvals.

2. LEGAL AND REGULATORY FRAMEWORK

A. MANUFACTURING AUTHORISATION

Manufacturers must obtain the applicable manufacturing licence and product-specific permissions required by Indian drug law. Where an RNA product qualifies as a new drug or biological product, the relevant approval requirements under the New Drugs and Clinical Trials Rules, 2019 must also be considered.

CDSCO guidance on biological products and vaccines emphasises quality, safety, efficacy, and adequate chemistry, manufacturing, and controls (CMC) documentation. The applicable requirements cannot be bypassed merely because the product uses an established manufacturing platform. <Cite refs={["turn262526search23","turn262526search25"]}/>

B. GOOD MANUFACTURING PRACTICES

Schedule M of the Drugs Rules, 1945 establishes applicable GMP requirements. Manufacturers must maintain suitable premises, qualified personnel, controlled equipment, documented procedures, quality-control systems, and reliable production records.

The manufacturing process should be validated to demonstrate consistent production of material meeting approved specifications. Deviations must be investigated, corrective and preventive actions documented, and batch release conducted by appropriately authorised personnel.

C. PRODUCT QUALITY AND CMC DOCUMENTATION

RNA products require a scientifically justified control strategy covering starting materials, the RNA drug substance, formulation components, and the finished product. Relevant quality attributes may include identity, integrity, purity, potency, concentration, stability, and contamination-related risks.

For lipid nanoparticle formulations, additional controls may be needed for particle characteristics, encapsulation, formulation consistency, and residual process impurities. Specifications and acceptance criteria must be scientifically justified and aligned with the applicable regulatory approval.

3. MODULARITY, CHANGE CONTROL, AND VALIDATION

A. PLATFORM REUSE

A validated platform can provide useful prior knowledge, but the manufacturer must establish which process elements remain comparable when the RNA sequence, formulation, scale, equipment, or intended indication changes. Prior validation cannot automatically establish the quality or safety of a materially different product.

B. CHANGE CONTROL

Changes to manufacturing sites, raw-material suppliers, equipment, analytical methods, formulation components, or process parameters must undergo documented risk assessment. Depending on their significance and the governing approval conditions, changes may require regulatory notification, approval, comparability studies, or additional validation.

C. TRACEABILITY AND DATA INTEGRITY

Manufacturers should maintain traceable records of raw-material lots, production steps, analytical results, deviations, batch decisions, and distribution. Electronic systems should protect records against unauthorised alteration and preserve reliable audit trails. These controls are particularly important where a common platform supplies several distinct RNA products.

4. LIABILITY FOR NON-COMPLIANCE

Failure to meet applicable manufacturing requirements may result in regulatory inspection findings, suspension or cancellation of licences, product recalls, restrictions on distribution, or prosecution where statutory offences are established.

Civil liability may also arise if defective production causes injury and the legal requirements for negligence, product liability, or another applicable cause of action are satisfied. Contract manufacturers, sponsors, suppliers, and quality-control laboratories may bear different responsibilities according to their statutory duties and conduct.

A platform's technical success does not excuse inadequate batch testing, failure to investigate contamination, misleading product claims, or distribution of a batch that does not meet applicable specifications.Regulatory references for further verification: The WHO's Regulatory Considerations for mRNA Vaccines discusses manufacturing controls and batch release; CDSCO's biological-products guidance explains India's regulatory expectations; and the European Medicines Agency's mRNA quality guideline provides comparative technical guidance for infectious-disease vaccines.

Important correction: The fifth item above is not a judicial precedent and should not be cited as case law. For formal legal work, use the six identified judgments and verify their citations against authoritative law reports before filing or publication.